Press releases

Venatorx Pharmaceuticals and GARDP partner to develop new antibiotic for hospital acquired infections with limited treatment options

|
Surgeons Hospital Bacteria Gardp Banner.jpg

GARDP and Venatorx Pharmaceuticals today announced a collaboration to accelerate the development of cefepime-taniborbactam, an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).

GARDP and Entasis Therapeutics initiate global phase 3 trial of zoliflodacin, a first-in-class oral antibiotic for the treatment of gonorrhoea

|
Gardp Gonorrhoea Phase 3 Trial Alabama 2.jpg

GARDP and Entasis Therapeutics (NASDAQ: ETTX) today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhoea. Following positive phase 2 results previously published in the New England Journal of Medicine (NEJM), Entasis and GARDP have partnered to complete late stage development, with GARDP fully-funding and sponsoring the global phase 3 trial.

Government of Principality of Monaco supports GARDP’s efforts to tackle drug-resistant sepsis in newborns

|
Monaco Parliment Gardp Amr.jpg

Ut enim deleniti maiores aut quibusdam adipisci odio deleniti qui optio commodi laudantium rerum earum minima sed ea aut est voluptatem ad commodi enim voluptas dolor ut optio nemo consectetur quasi ut voluptatibus quo fugiat harum sit molestias et et labore corporis vitae ea voluptas sit et fugiat aliquam corrupti voluptatem et rem non cum est voluptas enim delectus laboriosam.